Home > Medical Research Archives > Issue 149 > A New Era of HER2 Directed Therapy –A Review of Cardiac Toxicities in Novel AntiHER2 Agents
Published in the Medical Research Archives
Oct 2023 Issue
A New Era of HER2 Directed Therapy –A Review of Cardiac Toxicities in Novel AntiHER2 Agents
Published on Oct 26, 2023
DOI
Abstract
Overexpression of human epidermal growth factor receptor 2 (HER2) has classically been associated with decreased overall survival. HER2-positive breast cancer makes up about 15-20% of breast cancers. Overall survival and progression-free survival of HER2 breast cancers have increased due to advancements in therapies. Trastuzumab, a humanized monoclonal antibody, targets HER2 in patients with overexpression. When combined with anthracyclines, which has been the treatment of choice for many years, there is increased cardiotoxicity. Since the discovery of trastuzumab, there have been a myriad of novel agents that target HER2 receptors, however little is known about the cardiotoxic effects of these novel agents. In this review, we describe clinical trials using novel anti-HER2 agents for the treatment of HER2-positive breast cancer and the frequency and severity of cardiotoxicity of these agents.
Author info
Author Area
Have an article to submit?
Submission Guidelines
Submit a manuscript
Become a member